Please note that following on from information provided to NICE by the company in May 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 3948 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 07 November 2024 | Discontinued. Please note that following on from information provided to NICE by the company in May 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued |
| 10 May 2023 | For information, the company have announced that trial did not meet one of its dual primary endpoints (OS) and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 10 May 2023 | Suspended. For information, the company have announced that trial did not meet one of its dual primary endpoints (OS) and therefore they will no longer be pursuing a Marketing Authorisation Application in this indication at this time. Therefore, NICE has decided to suspend this appraisal from its current work programme. As this appraisal has been referred NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
For further information on our processes and methods, please see our CHTE processes and methods manual